January 2003
Worldwide Biotech;Jan2003, Vol. 15 Issue 1, p3
Trade Publication
Reports on the patent received by Pozen Inc. from the U.S. Patent and Trademark Office for MT 100, a product for treating migraine pain and association symptoms with less risk of cardiovascular side effects.


Related Articles

  • POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis.  // Biomedical Market Newsletter;6/30/2012, Vol. 21, p1 

    The article reports on an announcement made by POZEN Inc. related to the issue of a patent by the U.S. Patent and Trademark Office titled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs." It informs that the claims to pharmaceutical compositions containing aspirin and a...

  • News Headlines: Migraine.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p15 

    Reports on developments concerning the treatment of migraine. Pozen's submission of a New Drug Application for MT 300 for the acute treatment of migraine; Pfizer's receipt of approval for anti-migraine medicine relapse; Pozen's receipt of a new patent for MT 300.

  • Preliminary Injunction Ordered in POZEN Treximet Patent Litigation.  // Biomedical Market Newsletter;5/7/2011, p699 

    The article reports that the U.S. District Court for the Eastern District of Texas has granted a preliminary injunction ordering not to make use or sell Pozen Inc.'s Treximet for patent litigation. It provides an overview of the patent infringement lawsuit among Pozen, Par Pharmaceutical Cos....

  • Pozen builds marketing team as it preps drugs for market. Washkuch, Frank // Direct Marketing News;Oct2011, Vol. 33 Issue 10, p9 

    The article reports on the move of pharmaceutical firm Pozen Inc. to build its marketing staff and solicit digital advice from experts as it prepares for the digital marketing of its medical products in the U.S.

  • Pozen Patents Upheld in Treximet Patent Litigation.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p752 

    The article reports on the ruling of the U.S. District Court for the Eastern District of Texas concerning the litigation between Pozen Inc. and other generic drug companies which filed Abbreviated New Drug Applications (ANDAs). It says that the District Court ruled that Par Pharmaceutical Inc.,...

  • Sale keeps drugmaker healthy.  // Business North Carolina;Nov2012 Mid-Market, p10 

    The article features Pozen Inc., a Chapel Hill, North Carolina-based pharmaceutical company with two products that received approval from the U.S. Food and Drug Administration (FDA). GlaxoSmithKline PLC was commercializing Pozen's migraine medicine Treximet, which it co-developed under a...

  • Pharma: Clinic Roundup.  // BioWorld Today;2/11/2013, Vol. 24 Issue 28, p9 

    The article reports on two Phase III studies of PA32540 for ischemic strokes by Pozen Inc. which reduces endoscopic gastroduodenal ulcers rate.

  • News in brief . . .  // Reactions Weekly;8/13/2005, Issue 1064, p2 

    Presents news briefs related to pharmacology as of August 2005. Decision of POZEN Inc. to discontinue its development of naproxen sodium/metodopramide in the U.S.; Effect of cabergoline initiation on the behavior of patients.

  • POZEN Announces May 1 2012 Webcast of 1st Qtr 2012 Results.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article informs that POZEN Inc. has announced to release its financial results for first quarter 2012 on May 1, 2012 which will followed by a webcast.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics